If you have been reading about SR9009 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-11-28. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Disinfectants: Destroy or inactivate microorganisms (bacteria, fungi, viruses,) but may not act as sporicides (as those are the most difficult form to destroy). According to efficacy data, the EPA will classify a disinfectant as limited, general/ broad spectrum, or as a hospital disinfectant. Sanitizers: Reduce the number of microorganisms, but may not kill or eliminate all of them. Sterilizers (Sporicides): Eliminate all bacteria, fungi, spores, and viruses.
=== Racial controversies === Starbucks has been accused of racial bias and discrimination on several occasions. In 1994, Starbucks settled a lawsuit after two employees were dismissed because of their race, age, and sex. A black woman filed a suit after her direct supervisor, a regional vice president, said he would like to call her Toby, a slave name which was given to African Kunta Kinte in the TV miniseries Roots. Her co-worker spoke on her behalf, after which she was fired. In 2008, a former African American Starbucks engineer sued the company for discrimination after his supervisor failed to address racist bullying he was experiencing at the workplace, instead giving him extra work due to his complaining. Starbucks settled the suit in 2009. The Equal Employment Opportunity Commission has raised allegations against Starbucks for racial bias in its promotions, allegedly based on workforce data from 2007 to 2011 that showed that minority retail partners in the United States received fewer promotions than statistically expected. The 2015 Starbucks "Race Together" campaign, when baristas were instructed to write the phrase "Race Together" on customer's cups with the aim to start a national dialogue about race, was heavily criticized and received backlash. In 2020, employees were prohibited from wearing Black Lives Matter symbols or phrases on their clothing or accessories. Individual Starbucks cafes have faced criticism over incidents of racial bias, leading the company to close 8,000 cafes for a day in 2018 for racial bias training.
Bernd Michael Rode (July 14, 1946 – August 28, 2022) was an Austrian professor of chemistry at the University of Innsbruck and founder of the Austrian-South-East-Asian Academic University Network (ASEA-UNINET). Prof. Rode retired in 2011 but remained actively involved in teaching and research as well as in the thesis supervision.
Sources: en.wikipedia.org
nucleophile Any atom or molecule which can donate an electron pair to another atom or molecule. All molecules or ions with a free pair of electrons or at least one pi bond can act as nucleophiles, by which they are attracted to electron-deficient regions of other species; a chemical reaction involving a nucleophile donating an electron pair to an electrophile may be referred to as nucleophilic attack. Because they donate electrons, nucleophiles are Lewis bases by definition.
Kallikrein-6 is a protein that in humans is encoded by the KLK6 gene. Kallikrein-6 is also referred to as neurosin, protease M, hK6, or zyme. It is a 223 amino acid sequence, derived from its 244 original form, which contains a 16 residue presignal and 5 residue activation peptide.
=== Depapillation === In some diseases, there can be depapillation of the tongue, where the lingual papillae are lost, leaving a smooth, red and possibly sore area. Examples of depapillating oral conditions include geographic tongue, median rhomboid glossitis and other types of glossitis. The term glossitis, particularly atrophic glossitis is often used synonymously with depapillation. Where the entire dorsal surface of the tongue has lost its papillae, this is sometimes termed "bald tongue". Nutritional deficiencies of iron, folic acid, and B vitamins may cause depapillation of the tongue.
== Mechanism of action == Phenobarbital acts as an allosteric modulator which extends the amount of time the chloride ion channel is open by interacting with GABAA receptor subunits. Through this action, phenobarbital increases the flow of chloride ions into the neuron which decreases the excitability of the post-synaptic neuron. Hyperpolarizing this post-synaptic membrane leads to a decrease in the general excitatory aspects of the post-synaptic neuron. By making it harder to depolarize the neuron, the threshold for the action potential of the post-synaptic neuron will be increased. Direct blockade of glutamatergic AMPA and kainate receptors are also believed to contribute to the hypnotic and anticonvulsant effect that is observed with phenobarbital.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.